The National Institute for Health and Care Excellence

New treatment option recommended for recurrent or metastatic cervical cancer

A new treatment option is now available on the NHS for cervical cancer that has come back or spread to other parts of the body, following our final draft guidance published today.
The National Institute for Health and Care Excellence

From £1 to £180: how NICE guidance helped us make smarter slide sheet choices

NICE’s healthtech guidance provided me with the perfect catalyst for change.
The National Institute for Health and Care Excellence

First disease-modifying therapy to delay the onset of type 1 diabetes recommended for NHS use

Teplizumab is the disease-modifying therapy for type 1 diabetes and England is the first country in Europe to recommend it's use through a health technology appraisal.
National Institute for Health and Care Excellence

Quality statement 1: Empathy, dignity and respect

To have a good experience of NHS services people must be treated with empathy, dignity and respect. This is also fundamental for developing good relationships between people providing services and ...
National Institute for Health and Care Excellence

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] ...
National Institute for Health and Care Excellence

Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable

There is a commercial access agreement for daratumumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact jnj_imukcs@its.jnj.com ...
National Institute for Health and Care Excellence

Drug misuse

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
National Institute for Health and Care Excellence

Attention deficit hyperactivity disorder: diagnosis and management

This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well ...
National Institute for Health and Care Excellence

Rheumatoid arthritis in adults: management

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Neonatal parenteral nutrition

This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral ...
National Institute for Health and Care Excellence

Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy

We have moved interventional procedures guidance 615 to become HealthTech guidance 472. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...
National Institute for Health and Care Excellence

Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence

Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of ...